Abstract
Small-cell lung cancer (SCLC) cells express various markers of neuronal differentiation associated with deficient activity of the neuron-restricted silencer factor (NRSF). Here, we characterize mechanisms by which NRSF target genes are upregulated in SCLC and their functional consequences for cell survival. Since the glycine receptor (GlyR) α1 subunit gene, GLRA1, contains a sequence motif for NRSF binding (NRSE) within its 5′ UTR, it served as a cellular surrogate marker for NRSF activity. Expression of GLRA1 in nontransformed cells is largely restricted to cells in the spinal cord, retina and brain stem. In experiments described here, we detected GLRA1 transcripts in three out of four SCLC-derived cell lines and in three of five biopsy samples obtained from SCLCs. In contrast, no GLRA1 transcripts were found in 10 nonmalignant nor 15 non-small-cell lung cancer biopsies. Consistent with this observation, NRSF-mediated suppression of an expression construct harbouring the NRSE of the GLRA1 (GLRA1 NRSE) gene was impaired in three of four ‘classic’ SCLC cell lines, whereas exogenous overexpression of NRSF in NRSF-deficient SCLC cell lines reconstituted silencing of the reporter plasmid. The level of NRSF transcripts as well as the level of specifically bound NRSF to the NRSE correlated with the level of GLRA1 transcripts in SCLC cell lines. Splice variants encoding truncated NRSF proteins and expressed in some SCLC did not antagonize the repression of NRSE-containing genes. Most interestingly, reconstitution of NRSF expression induced apoptosis in SCLC cells, suggesting that inhibition of NRSF activity is a crucial step in the carcinogenesis of a subgroup of SCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andrews NC and Faller DV . (1991). Nucleic Acids Res., 19, 2499.
Betz H, Kuhse J, Schmieden V, Laube B, Kirsch J and Harvey RJ . (1999). Ann. NY Acad. Sci., 868, 667–676.
Breitinger HG and Becker CM . (2002). Chembiochem, 3, 1042–1052.
Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH and Minna JD . (1985). Cancer Res., 45, 2913–2923.
Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller YM, Frohman MA, Kraner SD and Mandel G . (1995). Cell, 80, 949–957.
Coulson JM, Edgson JL, Woll PJ and Quinn JP . (2000). Cancer Res., 60, 1840–1844.
Coulson JM, Fiskerstrand CE, Woll PJ and Quinn JP . (1999). Cancer Res., 59, 5123–5127.
Enz R and Bormann J . (1995). Vis. Neurosci., 12, 501–507.
Gossen M and Bujard H . (1992). Proc. Natl. Acad. Sci. USA, 89, 5547–5551.
Heasley LE . (2001). Oncogene, 20, 1563–1569.
Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, Rastelli L, Marin Dias CA, Levin V, Fuller GN, Echelard Y and Majumder S . (2000). Nat. Med., 6, 826–831.
Lee W, Mitchell P and Tjian R . (1987). Cell, 49, 741–752.
Magin A, Lietz M, Cibelli G and Thiel G . (2002). Neurochem. Int., 40, 195–202.
Monani U and Burghes AH . (1996). Genome Res., 6, 1200–1206.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C . (1991). J. Immunol. Methods., 139, 271–279.
Palm K, Belluardo N, Metsis M and Timmusk T . (1998). J. Neurosci., 18, 1280–1296.
Palm K, Metsis M and Timmusk T . (1999). Brain Res. Mol. Brain Res., 72, 30–39.
Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, Beckh S and Stuhmer W . (1999). EMBO J., 18, 5540–5547.
Parkin DM and Sankaranarayanan R . (1994). Anticancer Res., 14, 277–282.
Quinn JP, Bubb VJ, Marshall-Jones ZV and Coulson JM . (2002). Regul. Pept., 108, 135–141.
Schoenherr CJ and Anderson DJ . (1995). Science, 267, 1360–1363.
Schoenherr CJ, Paquette AJ and Anderson DJ . (1996). Proc. Natl. Acad. Sci. USA, 93, 9881–9886.
Scholl T, Stevens MB, Mahanta S and Strominger JL . (1996). J. Immunol., 156, 1448–1457.
Shimojo M, Lee JH and Hersh LB . (2001). J. Biol. Chem., 276, 13121–13126.
Shimojo M, Paquette AJ, Anderson DJ and Hersh LB . (1999). Mol. Cell. Biol., 19, 6788–6795.
Acknowledgements
We are indebted to Professor Dr med H Becker, Thoraxklinik der LVA Baden, Heidelberg for providing the endobronchial punch biopsies. We thank Professor Dr F Rösl, DKFZ, who kindly provided laboratory facilities and technical advice. We are also grateful to Dr rer nat L Jave Suárez and to Dr U Soto for excellent technical expertise and helpful discussions of the present study. Dr rer nat Werner Rittgen, Biostatistics Unit, DKFZ, performed the statistical analysis of the present data, which is gratefully acknowledged, and Mr Hexel for contributing FACS analysis of the apoptosis assay. Johannes Coy kindly helped in the analysis of mRNA profiles. This work was supported by a grant of the Tumorzentrum Heidelberg-Mannheim to Magnus von Knebel Doeberitz. This article is dedicated to Harald zur Hausen on the occasion of his retirement as head of the German Cancer Research Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gurrola-Diaz, C., Lacroix, J., Dihlmann, S. et al. Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells. Oncogene 22, 5636–5645 (2003). https://doi.org/10.1038/sj.onc.1206790
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206790
Keywords
This article is cited by
-
An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
Cancer Cell International (2023)
-
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Scientific Reports (2019)
-
REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer
Scientific Reports (2017)
-
An expression based REST signature predicts patient survival and therapeutic response for glioblastoma multiforme
Scientific Reports (2016)
-
Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma
BMC Cancer (2015)